NCT02367040已完成3 期
A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 458
- 试验地点
- 6
- 主要终点
- Progression Free Survival (PFS) Based on Independent Central Review.
研究概览
简要总结
The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in prolonging progression free survival (PFS) in patients with relapsed iNHL who have received one or more lines of treatment, including rituximab and who either had a treatment-free interval of ≥ 12 months after completion of the last rituximab-containing treatment, or who are unwilling to receive chemotherapy/for whom chemotherapy is contraindicated on reason of age, comorbidities, and/or residual toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of Indolent non-Hodgkin's lymphoma (iNHL) in CD20 positive patients, with histological subtype limited to:
- •Follicular lymphoma(FL) grade1-2-3a
- •Small lymphocytic lymphoma(SLL) with absolute lymphocyte count <5x10*9/L at study entry
- •Lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM)
- •Marginal zone lymphoma (MZL) (splenic, nodal, or extra-nodal)
- •Patients must have relapsed (recurrence after complete response or presented progression after partial response) after the last rituximab-, rituximab biosimilars-, or anti-CD20 monoclonal antibody (e.g. obinutuzumab)-containing therapy (other previous treatment lines after rituximab are allowed). A previous regimen is defined as one of the following: at least 2 months of single-agent therapy (less than 2 months of therapy is allowed for patients who responded to single-agent rituximab, rituximab biosimilars, or anti-CD20 monoclonal antibody); at least 2 consecutive cycles of polychemotherapy; autologous transplant; radioimmunotherapy. Previous exposure to PI3K is acceptable (except to copanlisib) provided there is no resistance. Patients with prior intolerance to PI3K inhibitors other than copanlisib are eligible.
- •Non-WM must have at least one bi-dimensionally measurable lesion (which has not been previously irradiated) according to the Lugano Classification. For patients with splenic MZL (Marginal-zone lymphoma) this requirement may be restricted to splenomegaly alone since that is usually the only manifestation of measurable disease.
- •Patients affected by WM who do not have at least one bi-dimensionally measurable lesion in the baseline radiologic assessment must have measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level ≥ 2 x upper limit of normal (ULN) and positive immunofixation test .
- •Male or female patients ≥ 18 years of age
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- •Life expectancy of at least 3 months
- •Availability of fresh tumor tissue and/or archival tumor tissue for central pathology(obtained within 5 years of the consent date) at Screening
- •Adequate baseline laboratory values collected no more than 7 days before starting study treatment
- •Left ventricular ejection fraction ≥ 45%
- •Patients must either:
- •have had a progression-free and treatment-free interval of at least 12 months after completion of the rituximab-, rituximab biosimilars-, or anti-CD20 monoclonal antibody-containing treatment OR
- •be considered unfit to receive chemotherapy on reason of age, concomitant morbidities, and/or residual toxicity from previous treatments, or unwillingness to receive chemotherapy. These patients must also have had a progression-free and treatment-free interval of at least 6 months after completion of the last rituximab-, rituximab biosimilars-, or anti-CD20 monoclonal antibody-containing treatment. Patients in whom chemotherapy is contraindicated are defined by one of the following features:
- •Age ≥ 80 years
- •Age < 80 years and at least 1 of the following conditions:
- •at least 3 grade 3 CIRS-G comorbidities OR
- •at least 1 grade 4 CIRS-G comorbidity (if compatible to participation in the study).
排除标准
- •Histologically confirmed diagnosis of follicular lymphoma grade 3b or transformed disease, or chronic lymphocytic leukemia
- •Progression free interval or treatment free interval of less than 12 months since the last rituximab-, rituximab biosimilars-, or anti-CD20 monoclonal antibody (e.g. obinutuzumab)-containing treatment(including maintenance with these drugs). For patients considered unwilling/unfit to receive chemotherapy : progression free interval or treatment free interval of less than 6 months since the last rituximab-, rituximab biosimilars-, or anti-CD20 monoclonal antibody-containing treatment (including maintenance with these drugs), as assessed by the investigator
- •History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function
- •Known lymphomatous involvement of the central nervous system
- •Patients with HbA1c > 8.5% at Screening
- •Known history of human immunodeficiency virus (HIV) infection
- •Hepatitis B (HBV) or hepatitis C (HCV). Patients positive for HBsAg or HBcAb will be eligible if they are negative for HBV-DNA, these patients should receive prophylactic antiviral therapy. Patients positive for anti- HCV antibody will be eligible if they are negative for HCV-RNA
- •Documented evidence of resistance to prior treatment with idelalisib or other PI3K inhibitors.
- •Prior treatment with copanlisib
- •Cytomegalovirus (CMV) infection. Patients who are CMV PCR positive at baseline will not be eligible.
研究组 & 干预措施
Copanlisib + Rituximab
Experimental
Combination of the Copanlisib and rituximab
干预措施: Copanlisib (Aliqopa, BAY80-6946) (Drug)
Copanlisib + Rituximab
Experimental
Combination of the Copanlisib and rituximab
干预措施: Rituximab (Drug)
Placebo + Rituximab
Placebo Comparator
Combination of Copanlisib placebo and rituximab
干预措施: Placebo (Drug)
Placebo + Rituximab
Placebo Comparator
Combination of Copanlisib placebo and rituximab
干预措施: Rituximab (Drug)
结局指标
主要结局
Progression Free Survival (PFS) Based on Independent Central Review.
时间窗: From first participant randomization (20-Aug-2015) up to data cut-off at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years and final analysis at 15-Nov-2024 up to 9 years
Progression-free survival (PFS) was defined as the time from randomization to progressive disease (PD) or death due to any cause, whichever was earlier according to the Lugano Classification and Response criteria in patients affected by Waldenström macroglobulinemia (kindly refer to the links in the Protocol section).
次要结局
- Objective Response Rate (ORR)(From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years)
- Complete Response Rate (CRR)(From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years)
- Duration of Response (DOR)(From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years)
- Disease Control Rate (DCR)(From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years)
- Time to Progression (TTP)(From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years)
- Overall Survival (OS)(From randomization up to the final analysis at 15-Nov-2024 up to 9 years)
- Time to Deterioration in DRS-P (Disease-Related Symptoms - Physical) of at Least Three Points, as Measured by the Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (FLymSI-18) Questionnaire.(From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years)
- Time to Improvement in DRS-P (Disease-Related Symptoms - Physical) of at Least 3 Points, as Measured by the Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 (FLymSI-18) Questionnaire.(From first participant randomization (20-Aug-2015) up to data cut-off date at primary completion (31-Aug-2020), approximately 5 years and 2-year follow-up after primary completion at 31-Aug-2022, up to 7 years)
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) at Primary Completion Date.(Up to 30 days after end of treatment with study drug, data reporting cut-off at 5 years from the first participant randomization date)
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) at 2-year Follow-up Cut-off Date.(Up to 30 days after end of treatment with study drug, data reporting cut-off at 7 years from the first participant randomization date)
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) at Final Analysis(Up to 30 days after end of treatment with study drug, data reporting cut-off at final analysis, up to 9 years)
研究者
研究点 (6)
Loading locations...
相似试验
终止
3 期
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)Lymphoma, Non-HodgkinNCT02626455Bayer551
进行中（未招募）
1 期
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate CancerNCT04253262Brown University13
终止
2 期
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell LymphomaDiffuse Large B-cell LymphomaNCT04433182Fondazione Italiana Linfomi - ETS37
进行中（未招募）
1 期
Clinical trial with Copanlisib in combination with Rituximab and Bendamustine in patients with Relapsed-Refractory Diffuse Large B-cell LymphomaEUCTR2019-004898-63-ITFONDAZIONE ITALIANA LINFOMI ONLUS81
终止
1 期
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast CancerAnatomic Stage IV Breast Cancer AJCC v8HER2-Positive Breast CarcinomaMetastatic Breast CarcinomaNCT04108858National Cancer Institute (NCI)2